The Ilera Effect starts here.

Our operation is staffed by experts—from management, to production, to processing, to the Pharmacists, Nurse Practitioners and Wellness Associates at our dispensary. We all share the same passion for making high-quality marijuana medicines available to people in need.

Management Team

Gregory Rochlin, CEO

Greg Rochlin is a serial entrepreneur, healthcare advocate and philanthropist. After graduating from the University of Maryland in 1987, Greg founded National Thermal Industries, a residential home improvement company, which he later sold to his business partner. From there, he moved into metals trading and recycling at Wise Recycling, which was the largest independent aluminum trading company in the world when he joined in 1992. Greg became the COO and eventually purchased the scrap division of the company, which was re-branded as Terrapin Recycling. Over the course of two decades, the company grew from processing 200,000 pounds of non-ferrous metal per month to more than ten million pounds per month, and diversified to include lucrative landfill, waste, and trucking services. Greg also founded Specialized Metal Solutions, an important supplier to the food container industry and metals trading firm, in 2006; he serves as CEO of the company. He is active in other industries as well – Greg is the CEO and co-owner of upscale Maryland wine and spirits chains and three real estate companies.

Greg has campaigned and volunteered tirelessly for healthcare causes throughout his life. A long-time Sinai Hospital of Baltimore board member and current chair, Greg was the last chair of the LifeBridge Health Planning Committee, which oversees the planning and budgeting for future projects at Sinai, Northwest and Carroll Hospital. He has also served on the board of Snyder Center for Aphasia Life Enhancement (SCALE), where he was instrumental in guiding the organization’s merger with the League of People with Disabilities of Maryland.

Greg has been the CEO of Ilera healthcare since its founding in 2016. Providing medical marijuana to patients gives him the opportunity to unite his business development acumen with his lifelong passion for compassion. His personal and professional experiences make him highly qualified to lead Ilera Healthcare.

Oludare Odumosu, COO

Dr. Odumosu brings 10 years of experience in corporate pharmaceutical business development, operations and strategic alliance management to his role as Ilera’s COO. His background in biochemistry and healthcare entrepreneurship gives him unique qualifications for this role. Dr. Odumosu played a critical role in Iroko Pharmaceutical’s post-clinical development of Zorvolex Tivorbex and Vivlodex through FDA approvals and successful US market commercialization. He also managed the execution of the business development gate processes for the expansion of Iroko’s Solumatrix franchise products through ex-US licensing agreement negotiations.

He received a PhD in Biochemistry and a Master’s in Public Health-Epidemiology and Biostatistics from the Loma Linda University School of Medicine and School of Public Health in Loma Linda, California; and a BS in Biology from Calvin College in Grand Rapids, Michigan. Dr. Odumosu is a World Bank Institute Certified public health professional with global healthcare translational/clinical/epidemiological research and data management experience.

Matt Pendleton, Director of Extraction and Processing

Mr. Pendleton has extensive experience in applying cGMP quality methodologies and advanced manufacturing processes to both startup and established manufacturers across a number of industries. He has established and refined processes for pharmaceutical, food and beverage, beer, spirits, and cannabis makers in the US, and now brings his experience and insight to the role of Director of Extraction and Processing for Ilera.

Matt graduated from The Pennsylvania State University, University Park, where he earned a Bachelor of Science degree in Chemical Engineering.

Andy Sack, Director of Cultivation

Andrew has a decade of experience in the agriculture grow arena, leading to his position as Chief Cultivation Officer at PRICH-Bio–Tech. He has created medical-quality and recreational product that exceeds patient and recreational user expectations.

Mr. Sack led a Colorado cultivation facility to recognition as a Colorado gold standard facility for professionalism and cleanliness in a cultivation facility. He also received a Cannabis Business Award for overseeing the medical dispensary of the year in 2015.

John Lorenston, Director Dispensing

Bio under construction

Board of Directors

Osagie Imasogie, Board Chair

Mr. Imasogie is the Co-Founder and Senior Managing Partner of PIPV Capital with over 30 years of experience in the fields of law, finance and business management, healthcare and the pharmaceutical industry. Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures in which he led his team in investing GSK R&D non-progressed assets into various companies and/or as the basis of starting new companies. Prior to this role within GSK, Osagie was a Vice President for Product Development Strategy at SmithKline Beecham. Prior to this role at SmithKline, he was the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals. He also previously served as a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck’s International, Manufacturing and Generic Drug Divisions.

Osagie has been a serial entrepreneur and has been founder and former CEO and/or Chairman of multiple life sciences companies, including Iroko Pharmaceuticals, iCeutica, Churchill Pharmaceuticals, Ception Therapeutics and Trigenesis Therapeutics. Osagie is also active in charitable and community pursuits and serves as a member of the Board of the Philadelphia Orchestra and the Philadelphia Museum of Art.

Osagie is an Adjunct Professor at the University of Pennsylvania Law School and also serves on the Law School’s Board of Overseers. In addition, he is a member of the Board of Trustees of the University of Pennsylvania and serves as the Chairman of the Budget & Finance Committee in addition to being a member of the Executive Committee. Osagie is a member of the New York State Bar.

Lisa Gray, Vice Chair

Ms. Gray has over 26 years of experience in finance, marketing, business development, and operations primarily within the pharmaceutical industry. Lisa is the Co-Founder and Managing Partner of PIPV Capital, a Private Equity firm focused on building companies in life sciences, where she manages the financial aspects of the firm, generates and leads investments, manages investor communications, and acts as CEO, Board Member and/or plays various management roles, as necessary. Prior to founding PIPV Capital, Lisa worked with SmithKline, Beecham Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, and Coopers and Lybrand.

Ms. Gray is a Certified Public Accountant (CPA) and Certified Valuation Analyst (CVA). She holds a Bachelor’s of Science in Accountancy from Villanova University, an MBA in Finance and a Postgraduate Degree in Marketing Management.

In addition, Lisa is active in various community efforts including YESUCAN, which is focused on improving lives of people with disabilities, The American Red Cross, The Villanova School of Business, and various youth programs.

Gregory Rochlin

Greg Rochlin is a serial entrepreneur, healthcare advocate and philanthropist. After graduating from the University of Maryland in 1987, Greg founded National Thermal Industries, a residential home improvement company, which he later sold to his business partner. From there, he moved into metals trading and recycling at Wise Recycling, which was the largest independent aluminum trading company in the world when he joined in 1992. Greg became the COO and eventually purchased the scrap division of the company, which was re-branded as Terrapin Recycling. Over the course of two decades, the company grew from processing 200,000 pounds of non-ferrous metal per month to more than ten million pounds per month, and diversified to include lucrative landfill, waste, and trucking services. Greg also founded Specialized Metal Solutions, an important supplier to the food container industry and metals trading firm, in 2006; he serves as CEO of the company. He is active in other industries as well – Greg is the CEO and co-owner of upscale Maryland wine and spirits chains and three real estate companies.

Greg has campaigned and volunteered tirelessly for healthcare causes throughout his life. A long-time Sinai Hospital of Baltimore board member and current chair, Greg was the last chair of the LifeBridge Health Planning Committee, which oversees the planning and budgeting for future projects at Sinai, Northwest and Carroll Hospital. He has also served on the board of Snyder Center for Aphasia Life Enhancement (SCALE), where he was instrumental in guiding the organization’s merger with the League of People with Disabilities of Maryland.

Greg has been the CEO of Ilera healthcare since its founding in 2016. Providing medical marijuana to patients gives him the opportunity to unite his business development acumen with his lifelong passion for compassion. His personal and professional experiences make him highly qualified to lead Ilera Healthcare.

Zoltan Kerekes

Zoltan has over 24 years of experience in the fields of law and business primarily within the pharmaceutical industry. Zoltan is Co-Founder and Managing Partner of PIPV Capital, a Private Equity firm focused on life sciences. Zoltan was Head of GlaxoSmithKline Ventures’ “Pure IP” transactions group and was Senior Patent Counsel for GlaxoSmithKline and previously was an attorney focused on intellectual property litigation and IP transactional work with White & Case, a preeminent global law firm based in NYC and Hopgood, Calimafde, Kalil & Judlowe (now Morgan Lewis), an intellectual property litigation boutique firm.

Zoltan has a BS in Biology from Fordham University and a JD from Boston University School of Law. He is a member of the New York State and Commonwealth of Massachusetts Bars. Zoltan is admitted to practice before the U.S. Patent and Trademark Office, the U.S. District Court for the Southern District of New York and the U.S. Court of Appeals for the Federal Circuit.

Torsten Geers

Mr. Geers is a Partner at Good Harbor Partners, LLC, an education advisory firm with deep expertise in educational technology, publishing, and digital media. Before joining Good Harbor Partners, Mr. Geers served as the Senior Vice President Corporate Development and Mergers and Acquisitions at Cengage Learning, one of the leading global education publishing companies. Mr. Geers also led the M&A and corporate development team at Thomson Reuters Healthcare and Science division. Prior to this, Mr. Geers was a VP for SAP AG where he served in a number of different corporate functions.

Mr. Geers has been involved with startups and emerging companies as an investor, co-founder, and advisor. Geers is a licensed attorney in Germany and the State of New York and began his career as an associate in the Business and Finance section of Morgan, Lewis & Bockius LLP, a leading US law firm.

Myles Norin

Mr. Norin, CEO of The Agora Companies, began his career in public accounting 30 years ago. As The Agora Companies was one of his first clients, he has been very involved in its success since the beginning of his career, and has watched Agora grow from revenues of less than $10 million to become a company that grosses over $1 billion annually. Mr. Norin is responsible for the day-to-day management of the company’s U.S. operations, and has helped lead Agora’s expansion efforts into England, France, Germany, Australia, South Africa, Brazil, as well as others. Under his leadership, Agora began their use of the internet as a tool for daily communications with newsletter subscribers as well as a sales vehicle. Agora now generates the majority of its revenue through e-commerce sales.

Shane A. Johnson, Outside Director

Dr. Johnson is the Founder and Managing Director of PaintBrush Capital Advisors. Prior to founding PaintBrush, Dr. Johnson served as a Manager with LEK Consulting, a global strategy consulting firm, and a Principal at Hamilton BioVentures, a Life Science venture capital firm. Dr. Johnson is currently the President of both SJ3D Holdings, Inc., a brand, asset and financial services company that serves the legal marijuana industry, and Farm to Farma, Inc., which owns intellectual property and brands including Trokie, a patent-pending pharmaceutical lozenge.

Dr. Johnson received a B.A. in Studio Art and a B.S. in Neuroscience (with honors) from Brown University, and was awarded an M.D. from the Stanford University School of Medicine. He is also a Fulbright Scholar.

Advisory Board

Stephanie Zarus

Ms. Zarus has over twenty-five years of experience both as an executive and health care pioneer. She has been a Vice President for Quality Initiatives, Marketing Development Officer, Chief Performance Officer and Chief Operating Officer. She co-founded Hospice Pharmacia, LLC and excelleRx.

Ms. Zarus was part of the founding team establishing the Mayes College of Healthcare Business and Policy, University of the Sciences in Philadelphia, where she served as Associate Dean and Assistant Professor of Pharmaceutical and Healthcare Business. Currently she serves as Dean’s Professor and Chair of the Board of Visitors. She currently leads the subcommittee for member services of the Adaptive Leadership Network (Harvard University), serves on the Medicinal Marijuana Review Panel (State of New Jersey, Department of Health) and is spearheading two working groups of the Vision 2020 Committee on Shared Leadership (Drexel University).

She holds a Bachelor of Science and Doctor of Pharmacy degrees from the Philadelphia College of Pharmacy and Science (PCPS). She completed Executive Certificate Programs from Harvard University’s Kennedy School Executive Education in the Art and Practice of Leadership Development and from the Kellogg Graduate School of Management of Northwestern University.

Michael N. Liebman, Ph.D.

Mr. Liebman is the Managing Director of IPQ Analytics, LLC and Strategic Medicine, Inc. His research focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective. He is active in research into areas related to international and US addictive behaviors and their relationship to health and is analyzing and comparing the long experience across the EU in medical marijuana with the early stage activities in the US. In addition, he is an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery, First Hospital of Wenzhou Medical University and Fudan University School of Medicine. He serves on 14 scientific advisory boards and the Board of Directors of the Nathaniel Adamczyk Foundation in Pediatric ARDS and Innovene Pharmaceuticals

Previously, Mr. Liebman was the Executive Director of the Windber Research Institute from 2003-2007. Prior to this, he was Director, Computational Biology and Biomedical Informatics, University of Pennsylvania Cancer Center 2000-2003. He served as Global Head of Computational Genomics, Roche Pharmaceuticals and Director, Bioinformatics and Pharmacogenomics, Wyeth Pharmaceuticals, Director of Genomics for Vysis, Inc. He is a co-founder of Prosanos, Inc (now United BioSource) (2000).

Brian Gimlett

Brian has more than 40 years of security experience in both the U.S. Government and the private sector.

Previously, Mr. Gimlett was the Senior Vice President and Chief Security Officer for NYSE Euronext. In this role, he was responsible for the security of the iconic New York Stock Exchange as well as NYSE locations in New Jersey, Chicago, and San Francisco. Internationally, he was responsible for Euronext options and stock exchanges in London, Paris, Amsterdam, Brussels, and Lisbon. In addition, Mr. Gimlett was in charge of security at the NYSE offices in Beijing, Hong Kong, Manila, Singapore, and Doha. Mr. Gimlett was the NYSE’s primary liaison with local, state, federal, international law enforcement, and intelligence agencies.

Before joining NYSE Euronext, he served as the Executive Director of Global Security for Wyeth Pharmaceuticals. Prior to Wyeth Pharmaceuticals, Mr. Gimlett worked at MBNA America Bank, during his tenure at MBNA, he also served an extended period of time as the Director of Employment. He spent 22 years with the U.S. Secret Service, where his last assignment was the Special Agent in Charge of the New York Office. He received a B.S. degree from the John Jay College of Criminal Justice.

Calvin B. Johnson M.D., M.P.H.

Dr. Johnson is the former Vice President and Chief Medical Officer of Temple University Health System and the former Secretary of Health for the Commonwealth of Pennsylvania. In that role, he served as senior advisor to the governor and directed the health-services and regulatory functions of Pennsylvania’s Department of Health, an agency with more than 1,500 employees and a budget of nearly $1 billion. Prior to serving the people of Pennsylvania, he was an Assistant Professor of Pediatrics at Temple University School of Medicine and a practicing pediatrician on the medical staff of Temple University Children’s Medical Center.

Dr. Johnson graduated from Morehouse College with a degree in chemistry. He earned his medical degree from the Johns Hopkins University School of Medicine and a master of public health degree from the Johns Hopkins University Bloomberg School of Public Health. He completed his training in pediatrics at the Children’s Hospital of Philadelphia.

Vince J. Kalish, Ph.D.

Dr. Kalish brings 30 years’ experience as a drug hunter and leader in medicinal chemistry, CMC, project leadership and the preclinical/early clinical development of drug candidates. He consults for start-up biotech companies as Kalish Biopharma Consulting. Previously he was a co-founder of Cardioxyl Pharmaceuticals and served as Senior Vice President, Chemistry and Pre-Clinical Development until acquisition by Bristol-Myers Squibb in December 2015 for $300 mil upfront.

Prior to joining Cardioxyl, Dr. Kalish held senior research management roles at biopharmaceutical companies including Idun Pharmaceuticals, Agouron Pharmaceuticals and Guilford Pharmaceuticals where he served as Senior Director of Medicinal Chemistry. Dr. Kalish is an inventor on numerous issued US patents and co-inventor of multiple compounds that have advanced into clinical trials including Viracept™, a marketed HIV protease inhibitor. Dr. Kalish earned his Ph.D. in organic chemistry from Penn State University and his B.S. from Rutgers University.